Vita 34 AG engages in the collection, storage, and distribution of cells, tissues, blood, and blood components for the purpose of medical applications. It also engages in the development of products and drugs based on cells, tissues, and blood for medical application. The firm produces and manufactures viral vectors and CAR-T cells. It operates through the Vita 34 and PBKM segments. The company was founded by Eberhard F. Lampeter on April 28, 1997 and is headquartered in Leipzig, Germany.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company